{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:08:46Z","timestamp":1793657326777,"version":"4.5.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T00:00:00Z","timestamp":1546819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Bellvitge University Hospital"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Mortality rates from Staphylococcus aureus bacteremia are high and have only modestly improved in recent decades. We compared the efficacies of a \u03b2-lactam in combination with daptomycin (BL\/D-C) and \u03b2-lactam monotherapy (BL-M) in improving clinical outcomes in methicillin-susceptible S. aureus (MSSA) bacteremia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective cohort study of MSSA bacteremia was performed in a tertiary hospital from January 2011 to December 2017. Patients receiving BL\/D-C and BL-M were compared to assess 7-, 30-, and 90-day mortality rates. A 1:2 propensity score matching analysis was performed. Differences were assessed using Cox regression models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 514 patients with MSSA bacteremia, 164 were excluded as they had received combination therapies other than BL\/D-C, had pneumonia, or died within 48 hours of admission. Of the remaining 350 patients, 136 and 214 received BL\/D-C and BL-M, respectively. BL\/D-C patients had higher Pitt scores and persistent bacteremia more often than BL-M patients. In the raw analysis, there were no differences in mortality rates between groups. After propensity score matching, there were no significant differences between the BL\/D-C (110 patients) and BL-M (168 patients) groups for all-cause mortality rates at 7 days (8.18% vs 7.74%; P = 1.000), 30 days (17.3% vs 16.1%; P = .922), and 90 days (22.7% vs 23.2%; P = 1.000), even in a subanalysis of patients with high-risk source of infection and in a subgroup excluding catheter-related bacteremia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>BL\/D-C failed to reduce mortality rates in patients with MSSA bacteremia. Treatment strategies to improve survival in MSSA bacteremia are urgently needed.<\/jats:p><\/jats:sec>","DOI":"10.1093\/cid\/ciz018","type":"journal-article","created":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T04:52:45Z","timestamp":1546663965000},"page":"1480-1488","source":"Crossref","is-referenced-by-count":37,"title":["Impact of \u03b2-Lactam and Daptomycin Combination Therapy on Clinical Outcomes in Methicillin-susceptible Staphylococcus aureus Bacteremia: A Propensity Score\u2013matched Analysis"],"prefix":"10.1093","volume":"69","author":[{"given":"Sara","family":"Grillo","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Bellvitge University Hospital, Barcelona"},{"name":"Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7075-943X","authenticated-orcid":false,"given":"Guillermo","family":"Cuervo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Bellvitge University Hospital, Barcelona"},{"name":"Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), Barcelona"},{"name":"Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00eda Infecciosa, Seville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Carratal\u00e0","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Bellvitge University Hospital, Barcelona"},{"name":"Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), Barcelona"},{"name":"Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00eda Infecciosa, Seville"},{"name":"University of Barcelona, Istituto de Salud Carlos III, Madrid"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Immaculada","family":"Grau","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Bellvitge University Hospital, Barcelona"},{"name":"Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), Barcelona"},{"name":"University of Barcelona, Istituto de Salud Carlos III, Madrid"},{"name":"Centro Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Respiratorias, Istituto de Salud Carlos III, Madrid"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat\u00e0lia","family":"Pallar\u00e8s","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, IDIBELL, L\u2019Hospitalet de Llobregat, Reus"},{"name":"Basic Clinical Practice Department, University of Barcelona, Reus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Teb\u00e9","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, IDIBELL, L\u2019Hospitalet de Llobregat, Reus"},{"name":"Basic Clinical Practice Department, Rovira Virgili University, Reus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lluisa","family":"Guillem Ti\u00f3","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Bellvitge University Hospital, Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Murillo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Bellvitge University Hospital, Barcelona"},{"name":"Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), Barcelona"},{"name":"Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00eda Infecciosa, Seville"},{"name":"University of Barcelona, Istituto de Salud Carlos III, Madrid"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0225-607X","authenticated-orcid":false,"given":"Carmen","family":"Ardanuy","sequence":"additional","affiliation":[{"name":"Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), Barcelona"},{"name":"University of Barcelona, Istituto de Salud Carlos III, Madrid"},{"name":"Centro Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Respiratorias, Istituto de Salud Carlos III, Madrid"},{"name":"Department of Microbiology, Bellvitge University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Angeles","family":"Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), Barcelona"},{"name":"Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00eda Infecciosa, Seville"},{"name":"University of Barcelona, Istituto de Salud Carlos III, Madrid"},{"name":"Department of Microbiology, Bellvitge University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Shaw","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Bellvitge University Hospital, Barcelona"},{"name":"Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), Barcelona"},{"name":"Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00eda Infecciosa, Seville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"Gudiol","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Bellvitge University Hospital, Barcelona"},{"name":"Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), Barcelona"},{"name":"Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00eda Infecciosa, Seville"},{"name":"University of Barcelona, Istituto de Salud Carlos III, Madrid"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Pujol","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Bellvitge University Hospital, Barcelona"},{"name":"Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), Barcelona"},{"name":"Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00eda Infecciosa, Seville"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,13]]},"reference":[{"key":"2019101504362950300_CIT0001","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jinf.2013.10.015","article-title":"Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies","volume":"68","author":"Kaasch","year":"2014","journal-title":"J Infect"},{"key":"2019101504362950300_CIT0002","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1469-0691.2012.03903.x","article-title":"The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study","volume":"19","author":"Laupland","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"2019101504362950300_CIT0003","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2019101504362950300_CIT0004","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/MD.0b013e318289ff1e","article-title":"Persistent Staphylococcus aureus bacteremia: a prospective analysis of risk factors, outcomes, and microbiologic and genotypic characteristics of isolates","volume":"92","author":"Chong","year":"2013","journal-title":"Medicine"},{"key":"2019101504362950300_CIT0005","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/cid\/cit499","article-title":"Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia","volume":"57","author":"L\u00f3pez-Cort\u00e9s","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2019101504362950300_CIT0006","doi-asserted-by":"crossref","first-page":"625.e1","DOI":"10.1016\/j.eimc.2015.03.015","article-title":"Diagnosis and treatment of bacteremia and endocarditis due to Staphylococcus aureus. A clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC)","volume":"33","author":"Gudiol","year":"2015","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2019101504362950300_CIT0007","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1086\/597031","article-title":"Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic","volume":"48","author":"Cosgrove","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2019101504362950300_CIT0008","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s15010-011-0189-2","article-title":"Combination therapy with an aminoglycoside for Staphylococcus aureus endocarditis and\/or persistent bacteremia is associated with a decreased rate of recurrent bacteremia: a cohort study","volume":"39","author":"Lemonovich","year":"2011","journal-title":"Infection"},{"key":"2019101504362950300_CIT0009","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1128\/AAC.00300-08","article-title":"Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus","volume":"52","author":"Riedel","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101504362950300_CIT0010","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0140-6736(17)32456-X","article-title":"Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Thwaites","year":"2018","journal-title":"Lancet"},{"key":"2019101504362950300_CIT0011","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijantimicag.2013.05.005","article-title":"Daptomycin: the role of high-dose and combination therapy for gram-positive infections","volume":"42","author":"Gould","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2019101504362950300_CIT0012","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"2019101504362950300_CIT0013","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1086\/383472","article-title":"Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens","volume":"38","author":"Carpenter","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2019101504362950300_CIT0014","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1128\/AAC.02192-12","article-title":"Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant \u03b2-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment","volume":"57","author":"Moise","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101504362950300_CIT0015","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin Ther"},{"key":"2019101504362950300_CIT0016","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2019101504362950300_CIT0017","doi-asserted-by":"crossref","first-page":"791","DOI":"10.7326\/0003-4819-137-10-200211190-00007","article-title":"Health care\u2013associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections","volume":"137","author":"Friedman","year":"2002","journal-title":"Ann Intern Med"},{"key":"2019101504362950300_CIT0018","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/SHK.0b013e318182f98f","article-title":"Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the acute physiology and chronic health evaluation II scoring systems","volume":"31","author":"Rhee","year":"2009","journal-title":"Shock"},{"key":"2019101504362950300_CIT0019","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"2019101504362950300_CIT0020","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1086\/313753","article-title":"Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis","volume":"30","author":"Li","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2019101504362950300_CIT0021","volume-title":"Breakpoint tables for interpretation of MICs and zone diameters, version 9.0","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2019"},{"key":"2019101504362950300_CIT0022","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Ser B"},{"key":"2019101504362950300_CIT0023","first-page":"1","article-title":"Propensity score methodology for confounding control in health care utilization databases","volume":"10","author":"Patorno","year":"2013","journal-title":"Epidemiol Biostat Public Heal"},{"key":"2019101504362950300_CIT0024","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2016"},{"key":"2019101504362950300_CIT0025","doi-asserted-by":"crossref","first-page":"948.e1","DOI":"10.1016\/j.cmi.2016.07.034","article-title":"Factors associated with 12 week case-fatality in Staphylococcus aureus bacteremia: a prospective cohort study","volume":"22","author":"Braquet","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2019101504362950300_CIT0026","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cir340","article-title":"Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding","volume":"53","author":"Dhand","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2019101504362950300_CIT0027","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1128\/AAC.02681-14","article-title":"Comparative efficacies of cloxacillin-daptomycin and the standard cloxacillin-rifampin therapies against an experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus","volume":"58","author":"El Haj","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101504362950300_CIT0028","doi-asserted-by":"crossref","first-page":"406.e1","DOI":"10.1016\/j.cmi.2016.08.026","article-title":"Combination antimicrobial therapy in patients with Staphylococcus aureus bacteremia\u2014a post hoc analysis in 964 prospectively evaluated patients.","volume":"23","author":"Rieg","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2019101504362950300_CIT0029","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1128\/AAC.01192-16","article-title":"Cefazolin and ertapenem, a synergistic combination used to clear persistent Staphylococcus aureus bacteremia","volume":"60","author":"Sakoulas","year":"2016","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz018\/28429944\/ciz018.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/69\/9\/1480\/30144901\/ciz018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/69\/9\/1480\/30144901\/ciz018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T20:48:44Z","timestamp":1720903724000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/69\/9\/1480\/5278707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,13]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,4,13]]},"published-print":{"date-parts":[[2019,10,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz018","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11,1]]},"published":{"date-parts":[[2019,4,13]]}}}